# Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

> **NCT07220785** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 28 (estimated)

## Conditions studied

- Generalized Lipodystrophy

## Interventions

- **DRUG:** Mibavademab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07220785
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-13
- **Primary completion:** 2028-05-19
- **Final completion:** 2028-09-08
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07220785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07220785, "Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07220785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*